Dr. Sarah Baxter Fisher, MD

Dr. Fisher practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Fisher's NPI, 1811139231, was assigned on March 31, 2009. Dr. Fisher graduated from University of Missouri, Columbia School of Medicine in 2009. Dr. Fisher's Texas license number on file is Q8883.

Dr. Fisher's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Fisher's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Texas Children's Hospital. Dmand AI also links Dr. Fisher to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fisher practices. Vendor and product names are available with a free account.

Surgery is Dr. Fisher's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Fisher is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Fisher's licenses on file in 10 states: Texas, Florida, Arizona, Tennessee, Washington, Alabama, Georgia, Louisiana, Mississippi and Oklahoma.

Dmand AI lists cancerous skin growth removal and thyroid surgery among the conditions Dr. Fisher treats.

CMS data shows 183 Medicare services from Dr. Fisher across 6 procedure codes in 2024, for 164 Medicare patients. Medicare paid $13,033 for them.

CMS counts 164 Medicare patients who saw Dr. Fisher in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fisher's median patient age at 71, with 57% women.

In 2024, Dr. Fisher wrote 28 Medicare Part D claims for 19 patients. 96% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $16 in total drug cost. In 2018, CMS named 17 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Fisher for performance year 2024, reported as part of a group. Dr. Fisher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fisher as offering telehealth. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. Fisher, more than 64% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 106 papers to Dr. Fisher, published from 2009 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Melanoma, Postoperative Complications and Thyroid Neoplasms. Dr. Fisher has published most often in Ann Surg Oncol. Dr. Fisher's most frequent co-authors are Nancy A. Perrier, MD, Elizabeth Gardner Grubbs, MD and Paul Hardin Graham, MD.

CMS Open Payments shows 6 general payments to Dr. Fisher from 4 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Eisai Inc. paid the most, $742.

Dr. Fisher graduated from University of Missouri, Columbia School of Medicine in 2009.

Dr. Fisher is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.